972 related articles for article (PubMed ID: 25481442)
1. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
[TBL] [Abstract][Full Text] [Related]
2. Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms.
Armijo LM; Wawrzyniec SJ; Kopciuch M; Brandt YI; Rivera AC; Withers NJ; Cook NC; Huber DL; Monson TC; Smyth HDC; Osiński M
J Nanobiotechnology; 2020 Feb; 18(1):35. PubMed ID: 32070354
[TBL] [Abstract][Full Text] [Related]
3. Polyanion-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
Craparo EF; Porsio B; Schillaci D; Cusimano MG; Spigolon D; Giammona G; Cavallaro G
Nanomedicine (Lond); 2017 Jan; 12(1):25-42. PubMed ID: 27879162
[TBL] [Abstract][Full Text] [Related]
4. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L
Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Aerosolized Rifaximin versus Tobramycin for Treatment of Pseudomonas aeruginosa Pneumonia in Mice.
Kirby BD; Al Ahmar R; Withers TR; Valentine ME; Valentovic M; Long TE; Gaskins JR; Yu HD
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010865
[No Abstract] [Full Text] [Related]
6. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
Strateva T; Petrova G; Mitov I
J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
[TBL] [Abstract][Full Text] [Related]
7. Nano-antibiotics in chronic lung infection therapy against Pseudomonas aeruginosa.
Hadinoto K; Cheow WS
Colloids Surf B Biointerfaces; 2014 Apr; 116():772-85. PubMed ID: 24656614
[TBL] [Abstract][Full Text] [Related]
8. Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics.
Hasan MA; Lange CF
J Aerosol Med; 2007; 20(3):282-93. PubMed ID: 17894535
[TBL] [Abstract][Full Text] [Related]
9. PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
Bahamondez-Canas TF; Zhang H; Tewes F; Leal J; Smyth HDC
Mol Pharm; 2018 Apr; 15(4):1643-1652. PubMed ID: 29514003
[TBL] [Abstract][Full Text] [Related]
10. [Use of inhaled tobramycin in patients with cystic fibrosis].
Chermenskiĭ AG; Gembitskaia TE
Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
[TBL] [Abstract][Full Text] [Related]
11. Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa.
Halwani M; Hebert S; Suntres ZE; Lafrenie RM; Azghani AO; Omri A
Int J Pharm; 2009 May; 373(1-2):141-6. PubMed ID: 19429299
[TBL] [Abstract][Full Text] [Related]
12. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL
J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222
[TBL] [Abstract][Full Text] [Related]
13. Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa.
Murphy RA; Coates M; Thrane S; Sabnis A; Harrison J; Schelenz S; Edwards AM; Vorup-Jensen T; Davies JC
Microbiol Spectr; 2022 Aug; 10(4):e0081322. PubMed ID: 35727066
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
[TBL] [Abstract][Full Text] [Related]
15. A Low-Molecular-Weight Alginate Oligosaccharide Disrupts Pseudomonal Microcolony Formation and Enhances Antibiotic Effectiveness.
Pritchard MF; Powell LC; Jack AA; Powell K; Beck K; Florance H; Forton J; Rye PD; Dessen A; Hill KE; Thomas DW
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630204
[TBL] [Abstract][Full Text] [Related]
16. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Cheer SM; Waugh J; Noble S
Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
[TBL] [Abstract][Full Text] [Related]
17. A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.
Sawicki GS; Ayyagari R; Zhang J; Signorovitch JE; Fan L; Swallow E; Latremouille-Viau D; Wu EQ; Shi L
Pediatr Pulmonol; 2013 Oct; 48(10):954-61. PubMed ID: 23255309
[TBL] [Abstract][Full Text] [Related]
18. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis.
Barclay ML; Begg EJ; Chambers ST; Thornley PE; Pattemore PK; Grimwood K
J Antimicrob Chemother; 1996 Jun; 37(6):1155-64. PubMed ID: 8836818
[TBL] [Abstract][Full Text] [Related]
19. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
20. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
Ratjen F; Brockhaus F; Angyalosi G
J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
